Periungual Injection of the Novel IL-17A Inhibitor Xeligekimab Combined with Tofacitinib for Acrodermatitis Continua of Hallopeau (ACH): A Prospective, Real-World, 12-Week Study (EADV-Sp 2026) - May 13, 2026 - Abstract #P0161; ID-674; "(C) Comparison of Dermatology Life Quality Index(DLQI) scores between baseline and post-12-week treatment. Boxes include the median and interquartile range.**P<0.05 by Student's t-test Conclusions This preliminary study demonstrates that periungual xeligekimab combined with tofacitinib is an effective and well- tolerated therapeutic strategy for refractory ACH, offering significant improvements in both nail signs and quality of life."
Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • Pustular Psoriasis • Respiratory Diseases • IL17A
|
|
Anqi Liu 1; Zhiying Yu1; Meng Wang1; Shaohui Geng2; Ying Yang1; Chen Li1
|